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endothelial cells.
Background. Advanced glycation end-products (AGEs),
which are formed in aging, diabetes mellitus, and kidney fail-
ure are implicated in the occurrence of vascular complications.
We, thus, evaluated in cultured endothelial cells, the AGEs’ ef-
fect on gene expression and synthesis of tumor necrosis factor-a
(TNF-a) and endothelial nitric oxide synthase (eNOS) mRNA
and protein expression, which may be involved in vascular re-
modeling.
Methods. Human umbilical vein cords endothelial cells (HU-
VEC) were stimulated with AGE-specific compounds [AGE-
human serum albumin (AGE-HSA), Ne-carboxymethylysine
(CML), AGE-b2 microglobulin (AGE-b2m)], and there-
after, incubated with interleukin1-a, lipopolysaccharide, and
interferon-c.
Results. mRNA expression and secretion of TNF-a were sig-
nificantly enhanced after incubation with AGE-HSA, CML,
and AGE-b2m compared to that found in HUVEC incubated
with HSA or b2m. AGE-HSA, CML, and AGE-b2m induced
a significant decrease in eNOS protein and mRNA expression.
Conclusion. AGEs promote mRNA expression and secretion
of TNF-a and reduce eNOS mRNA and protein expression in
HUVEC. Such changes may play a role in the vascular dys-
function and the development of vasculopathy seen in diabetes,
uremia, and old age.
Reducing sugars, such as glucose, react nonenzymat-
ically with the amino groups of proteins to form stable
Amadori products through Schiff base adducts. Amadori
products undergo a series of changes during a period of
weeks to months, thereby forming advanced glycation
end-products (AGEs) [1, 2]. Once formed, AGEs are,
by nature, irreversible. Most are characterized by a dis-
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tinct fluorescence and a propensity to cross link proteins
[3, 4]. From the large number of AGEs only a few have
been characterized chemically and identified in tissues,
including Ne-carboxymethylysine (CML), pentosidine,
pyrraline, and imidazolone. In diabetes, renal failure, and
natural aging, AGEs accumulate rapidly in different
tissues [5], playing a role in the pathogenesis of var-
ious complications, particularly in the development of
atherosclerosis [5–8]. In such conditions, mononuclear
phagocytes, vascular smooth muscle cells, and endothelial
cells are activated through AGEs receptors [9–11]. More-
over, in renal failure, there is a unique setting for AGE
formation on b2 microglobulin (b2m) [12], implicated in
renal failure complications.
Endothelial cells are producers of and targets for cy-
tokines [13, 14]. They are responsive to interleukin-1
or TNF-a and, when activated, secrete proinflammatory
cytokines such as IL-6, IL-8, granulocyte-macrophage
colony-stimulating factor (GM-CSF) [13], and TNF-a
[14], leading to an increased expression of membrane ad-
hesion molecules [15].
To our knowledge, the effects of human-prepared
AGEs on human endothelial cell production of TNF-
a are not known. However, it has been demonstrated
that cytokines stimulate the production of TNF-a and
expression of TNF-a mRNA. Because TNF-a and AGEs
have been implicated in the development of macro- and
microangiopathy in diabetes, we have undertaken the
present in vitro study to test the concept that AGEs may
stimulate TNF-a production by human umbilical vein
cord endothelial cells (HUVEC). Because TNF-a and
AGEs are known to affect eNOS expression in cultured
endothelial cells, we have, in the same set of experiments,
evaluated the expression of eNOS mRNA and eNOS pro-
tein. Three different AGEs compounds were used: AGE-
human serum albumin (AGE-HSA), the most frequently
applied in experimental studies, CML, the most preva-
lent AGEs detected in vivo [16] with high affinity for
receptor of AGEs (RAGE) [17], and AGE-b2
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microglobulin (AGE-b2m), which is increased in urine
and serum of uremic patients [12].
Our study could show that, in HUVEC, the three dif-
ferent AGEs had a similar stimulating action on the pro-
duction and mRNA expression of TNF-a and a similar
inhibiting action on eNOS mRNA and eNOS protein
expression.
METHODS
Preparation of AGE-HSA and AGE-b2m
AGE-HSA and AGE-b2m were prepared as previ-
ously described [12]. Briefly, HSA (fraction V, 1.5 mmol/
L, Sigma, Rehovot, Israel) or b2m (0.17 mmol/L, ICN,
Irvine, CA, USA) were dissolved with 1 mol/L (for AGE-
HSA preparation) or 0.1 mol/L (for AGE-b2m) of glu-
cose (Riedel-de Haen, Seelze, Germany) in 100 mmol/
L sodium phosphate buffer (pH 7.4) containing 200 U/mL
of penicillin, 200 lg/mL streptomycin, 80 lg/mL of gen-
tamycin, and 1.5 mmol/L of phenylmethylsulfonylfluo-
ride (PMSF) under sterile conditions. Sterilization was
initially performed with 0.22-lm pore size filters, after
which the solution was incubated for 60 days in the
dark at 37◦C. After incubation, the solution was dialyzed
overnight against phosphate-buffered saline (PBS). The
HSA or b2m controls were subjected to the same pro-
cedure (except for the presence of glucose in the incu-
bating solution) as that used for AGEs. Endotoxin levels
in all samples were measured by Limulus amoebocyte
lysate assay (E-Toxate, Sigma), and were found to be
less than 0.2 ng/mL (corresponding to 0.96 EU/mL). Our
preliminary studies showed that a significant TNF-a or
eNOS mRNA changes were seen at endotoxin concentra-
tions >1 lg/mL. The concentration of AGE-HSA, AGE-
b2m, HAS, and b2m were determined by the method of
Bradford.
Synthesis and characterization of
Ne-carboxymethyllysine (CML)
HSA (fraction V, 2.64 mmol/L) and sodium cyanoboro-
hydride (0.03 to 0.45 mol/L) were dissolved in sodium
phosphate buffer (0.2 mol/L; pH 7.8); to this was added in-
creasing concentrations of gloxylic acid (0.01 to 0.155 mol/
L) in a total volume of 1 mL per reaction. The mixture
was incubated for 24 hours at 37◦C. Control HSA was pre-
pared under the same conditions, except that gloxylic acid
was omitted [17]. Preparations of CML-modified HSA
were extensively dialyzed versus PBS and characterized
by percent modification as determined by employment
of 2,4,6-trinitrobenzene sulfonic acid to determine the
difference in lysine residues of modified versus unmodi-
fied preparations [18]. The solutions were passed through
0.22-lm pore size filters to remove possible contamina-
tion. Final products contained less than 0.2 ng/mL (cor-
responding to <0.96 EU/mL) of endotoxin (E-Toxate,
Sigma).
Measurement of AGEs
AGE-HSA and AGE-b2m fluorescence was measured
with excitation/emission 370/440 nm on the spetrofluo-
rophotometer RF-1501 (Shimadzu, Japan). AGEs were
also evaluated by enzyme-linked immunosorbent assay
(ELISA) using anti-AGE-mouse monoclonal antibody
(clone 6D, Wako Chemicals, Richmond, VA, USA) [16].
Endothelial cell culture and incubation
Endothelial cell cultures were obtained from umbili-
cal cords according to the method of Jaffe et al [19]. The
Ethics Review Committee approved the study, and the
parturient gave written informed consent. Only umbili-
cal cords from women who had normal pregnancy and
birth were used. Fresh umbilical cord vein were rinsed
with PBS, filled with solution containing collagenase H
(0.3%, Roche Diagnostic GmbH, Penzberg, Germany)
in PBS, and incubated at 37◦C for 20 minutes. The col-
lagenase solutions were removed, and the veins washed
with PBS. Human umbilical cord vein endothelial cells
(HUVEC) were collected by centrifugation at 1500 rpm
for 10 minutes and then seeded in culture flasks coated
with fibronectin (Biological Industries, Kibbutz Beit-
Haemek, Israel). The HUVEC were grown in M-199
medium supplemented with 20% fetal calf serum (FCS),
100 U/mL penicillin, 100 lg/mL streptomycin (Biological
Industries), 0.25 lg/mL amphothericin, 5 U/mL heparin,
25 lg/mL endothelial mitogen (Biomedical Technologies,
Inc., Stoughton, MA, USA) under standard cell cul-
ture conditions (humidified atmosphere, 5% CO2, 37◦C).
Cultured cells were identified as endothelial by their mor-
phology and the presence of von Willebrand factor. Con-
fluent cultures of HUVEC were used for experiments
at passages 2 to 4. HUVEC (5 × 105/1 mL) were incu-
bated in 6-well tissue culture plates (Corning, NY, USA)
in the presence of different concentrations of AGE-HSA,
AGE-b2m, CML, HSA, and b2m (25 to 200 lg/mL) for 24
to 72 hours. The cells were then stimulated with the com-
bination of interleukin-a (IL-1 a), 1 ng/mL (R&D Sys-
tems, Minneapolis, MN, USA), lipopolysacharide (LPS),
2 lg/mL (Sigma), and interferon-c (IFN) 20 ng/mL
(107 U/mg, R&D Systems), ILF for 6 hours (mRNA
expression) or 24 hours (cytokine secretion). The ILF
definition is IL-1 a, LPS, IFN. The combination and the
concentration of ILF were chosen supported by sev-
eral calibration experiments. Each experiment included
all the controls and experiments groups that were
investigated.
Inhibition of AGEs’ interaction with receptor of AGEs
(RAGE) was assessed using a mouse IgG2a monoclonal
anti-RAGE antibody (Chemicon, Temecula, CA, USA).
Endothelial cells were preincubated for 3 hours with
20 lg/mL anti-RAGE antibody or 20 lg/mL mouse IgG2a
isotype control (Chemicon) prior to AGEs stimulation.
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Reverse transcriptase-polymerase chain
reaction (RT-PCR)
Expression of TNF-a and eNOS genes was performed
by a semiquantitative multiplex RT-PCR technique. To-
tal RNA was extracted from endothelial cells using the
PUREscript RNA isolation kit (Gentra Systems, Inc.,
Minneapolis, MN, USA), according to the manufac-
turer’s instructions. RNA (1 lg) was then reverse tran-
scribed into single-stranded DNA with 200 U of SUPER-
SCRIPTTMII RNase Reverse Transcriptase (Life Tech-
nologies, Gibco BRL, Gaithersburg, MD, USA), and
oligo (dT)15 primer (Promega) at 37◦C for 45 minutes,
42◦C for 15 minutes, and 99◦C for 5 minutes. PCR ampli-
fication was performed on 1/10th of the cDNA solution
with 0.5 U of Taq DNA polymerase (Sigma) at a final
volume of 50 lL. The PCR conditions and primers se-
quence were as follows: for TNF-a mRNA amplification:
Forward primer- 5′-GCTTGTTCCTCAGCCTCTTC- 3′,
Reverse primer: 5′-GGTTATCTCTCAGCTCCACGC-
3′, generating a 278-bp PCR product. For eNOS mRNA
amplification: Forward primer- 5′-CCCCTGCACTATG
GAGTCTG- 3′, Reverse primer: 5′-CGTGAGCCCAA
AATGTCTTC- 3′, generating a 582-bp PCR prod-
uct. b-actin primers sequence: Forward primer: 5′-
GAGACCTTCAACACCCCAGC-3′, Reverse primer:
5′-GCTCATTGCCAATGGTGATG-3′, generating a
388-bp PCR product. PCR program for TNF-a: 30 cycles
of 94◦C, for 30 seconds, 60.3◦C for 30 seconds, and 72◦C
for 30 seconds. PCR program for eNOS: 30 cycles of 94◦C
for 30 seconds, 60.8◦C for 30 seconds, and 72◦C for 30 sec-
onds. All primers were chosen to be complementary to
domains in different exons to avoid false-positives caused
by DNA contamination of the RNA preparations. RT-
PCR products were separated on 1.5% agarose (Sigma).
TNF-a immunoassay
TNF-a in culture supernatants was measured us-
ing a commercial enzyme-linked immunosorbent assay
(ELISA) kit (Endogen, Woburn, MA, USA), sensitivity
of <2 pg/mL.
Western blot analysis
Proteins from endothelial cells incubated with AGE-
HSA or HSA for 72 hours were extracted in a lysis buffer
containing 50 mmol/L Tris-HCl, 0.1 mmol/L EGTA,
0.1 mmol/L EDTA, 5 mmol/L sodium fluoride, 1 mmol/L
sodium pyrophosphate, 1 mmol/L sodium vanadate,
1 mmol 4-(2-aminoethyl)-benzenesulfonyl fluoride, pro-
tease inhibtor cocktail tablet (Roche Diagnostics
GmbH), 1% (vol/vol) Igepal ca630, 0.1% sodium dode-
cyl sulfate (SDS), and 0.1% deoxycholate, pH 7.5. After
10 minutes of incubation on ice, nuclei and cell debris
were removed by centrifugation at 10,000g for 10 min-
utes at 4◦C. The protein content was measured using
the BCATM (bicinchoninic acid) protein assay method
(Pierce, Rockford, IL, USA). The Pierce BCATM protein
assay is a highly sensitive reagent for the quantitative col-
orimetric determination of total protein in dilute aqueous
solutions.
Total proteins (20 lg) were separated by 7.5% SDS-
polyacrylamide gels and electrophoretically transferred
to a nitrocellulose membrane. After blocking with 5%
milk, the membranes were incubated with eNOS mon-
oclonal antibody (1:2000; Transduction Labs, Lexington,
KY, USA) and then washed with Tris-buffered saline con-
taining 0.1% Tween and incubated with sheep antimouse
immunoglobulin (Ig) conjugated with horseradish perox-
idase. The results were developed using chemilumines-
cent reporter system (ECL reagents). The expression of
eNOS protein was detected as a single band at 136 kD.
Statistical analysis
The results are expressed as mean ± SE. Data distri-
bution was determined as normal. Multiple comparisons
between different groups were performed with one-way
analysis of variance (ANOVA) and also Student paired
t test. The data were also evaluated by nonparamet-
ric tests (Friedman and Kruskal-Wallis) when small test
numbers were present. P values of less than 0.05 were
considered significant when found in all statistical tests.
RESULTS
Effect of AGEs on TNF-a production by ILF (IL1-a, LPS,
IFN-c)-stimulated HUVEC
Figure 1 shows the effect of AGE-HSA (Fig. 1A), CML
(Fig. 1B), and AGE-b2m (Fig. 1C) on TNF-a secretion.
TNF-a was undetectable in the supernatant of nonstim-
ulated HUVEC. Exposure of HUVEC to ILF (IL-1 a,
LPS, and IFN) for 24 hours induced the production of
TNF-a. AGE-HSA increased further the TNF-a pro-
duction as compared to HSA (25 lg/mL: 263 ± 30 vs.
192 ± 40 pg/106 cells, NS; 50 lg/mL: 372 ± 21 vs. 164 ±
67 pg/106 cells, P = 0.013; 100 lg/mL: 389 ± 35 vs. 139 ±
51 pg/106 cells, P = 0.002). There was significant differ-
ence between 25 lg/mL and 100 lg/mL AGE-HSA (P <
0.05), suggesting the presence of a dose-dependent ef-
fect. HSA had no significant effect on TNF-a production
compared to basal conditions.
The effect of CML on TNF-a secretion was also char-
acterized by an increased production (Fig. 1B) compared
to HSA (50 lg/mL: 228.8 ± 53.7 vs. 48 ± 17.8 pg/106 cells,
P = 0.018; 100 lg/mL: 294.7 ± 16.6 vs. 73.5 ± 36.5 pg/106
cells, P = 0.002; 200 lg/mL: 324 ± 54 vs. 72.5 ± 35.2 pg/106
cells, P = 0.005).
AGE-b2m had a similar effect (Fig. 1C) compared to
the action of b2m (50 lg/mL: 336.98 ± 172.9 vs. 37.5 ±
37.5 pg/106 cells, P = 0.026; 100 lg/mL: 340.7 ± 109.5 vs.
44.5 ± 44.5 pg/106 cells, P = 0.003; 200 lg/mL: 449.7 ±
98.6 vs. 71.9 ± 15.2 pg/106 cells, P = 0.001). There were no
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Fig. 1. Effect of advanced glycation end-
products (AGEs) on tumor necrosis factor-
a (TNF-a) production by stimulated human
umbilical vein cords endothelial cells (HU-
VEC). HUVEC were incubated for 24 hours
with increasing concentrations of AGE-HSA
(A), CML (B), AGE-b2m (C), HSA, and b2m
(0 to 200 lg/mL). The cells were then stimu-
lated by IL-1 a (1 ng/mL), LPS (2 lg/mL), and
IFN (200 U/mL) (ILF) for 24 hours. Cell-free
supernatant was collected and tested for TNF-
a. The results are expressed as mean ± SE of
4 to 6 experiments. ∗P < 0.05 vs. HSA or b2m.
#P < 0.05 vs. 25 lg/mL AGE-HSA. Abbrevi-
ations are: AGE-HSA, HUVEC incubated in
the presence of AGE-HSA followed by ILF;
CML, HUVEC incubated in the presence of
CML followed by ILF; AGE-b2m, HUVEC
incubated in the presence of AGE-b2m fol-
lowed by ILF; HSA, HUVEC incubated in the
presence of HSA followed by ILF; b2m, HU-
VEC incubated in the presence of b2m fol-
lowed by ILF; 0, HUVEC cultured in medium
followed by ILF.
significant differences between different concentrations
of AGE-b2m or CML.
Effect of AGEs on TNF-a gene expression
by ILF-stimulated HUVEC
TNF-a mRNA was expressed in HUVEC stimulated
for six hours with ILF (0), but not in nonstimulated HU-
VEC (0-ILF) (Fig. 2). HSA or b2m had no effect on
TNF-a mRNA expression in ILF-stimulated HUVEC.
AGE-HSA, CML, and AGE-b2m (50 to 200 lg/mL)
increased the expression of TNF-a mRNA in ILF-
stimulated HUVEC compared to HUVEC incubated
with HSA or b2m (Fig. 2). The relative fold of TNF-a
signal is plotted against HSA or b2m in Table 1, show-
ing that AGE-HSA, CML, and AGE-b2m significantly
increased the expression of TNF-a mRNA in a dose-
dependent manner.
Effect of AGEs on eNOS gene expression
by ILF-stimulated HUVEC
HUVEC with no stimulation expressed eNOS mRNA
(Fig. 3). Six hours of incubation with ILF decreased the
expression of eNOS by HUVEC. AGE-HSA, CML, and
AGE-b2m further decreased the expression of eNOS
in ILF-stimulated HUVEC compared to HSA or b2m
(Fig. 3). The eNOS signal is plotted against HSA or b2m
in Table 2, showing that AGE-HSA, CML, and AGE-
b2m decreased the eNOS mRNA expression.
Effect of AGE-HSA and CML on eNOS gene expression
by nonstimulated HUVEC
HUVEC exposed to AGE-HSA and CML for 48 hours
had a reduced eNOS mRNA expression compared to
HSA (Fig. 4).
Effect of anti-RAGE antibody on the reduction of eNOS
mRNA expression induced by AGE-HSA
To ensure that the effects of AGEs were mediated
through receptor of AGEs (RAGE), inhibition of AGEs
interaction with RAGE was assessed by using mono-
clonal anti-RAGE antibodies (Fig. 5). Preincubation of
HUVEC with anti-RAGE antibodies inhibited the reduc-
tion of eNOS mRNA expression induced by AGEs [in
both ILF-stimulated (Fig. 5A) and nonstimulated HU-
VEC (Fig. 5B)].
Effect of anti-RAGE antibody on the stimulation of
TNF-a mRNA expression induced by AGE-HSA
Preincubation of HUVEC with anti-RAGE antibod-
ies inhibited the increased TNF-a mRNA expression in-
duced by AGE-HSA in ILF-stimulated HUVEC (Fig. 6).
Effect of AGE-HSA on eNOS protein levels by
nonstimulated HUVEC
We examined whether the reduction in eNOS mRNA
expression is associated with a decrease in eNOS protein
levels. HUVEC exposed to AGE-HSA for 72 hours had
a reduced eNOS protein expression (Fig. 7).
DISCUSSION
AGEs have been implicated in the pathogenesis of
atherosclerosis and diabetic microangiopathy [7, 20] due,
at least in part, to their action on vascular cells [9–11].
This is the reason why we have decided to evaluate the
possible effect of in vitro prepared AGEs on cultured
endothelial cells, measuring their impact on TNF-a and
eNOS production. Three different AGEs were prepared
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Fig. 2. Effect of advanced glycation end-products (AGEs) on tumor
necrosis factor-a (TNF-a) gene expression by stimulated human umbil-
ical vein cords endothelial cells (HUVEC). HUVEC were incubated for
24 hours with increasing concentrations of AGE-HSA (A), CML (B),
AGE-b2m (C), HSA, or b2m (0 to 200 lg/mL). The cells were then
stimulated by ILF for 6 hours. Total RNA was extracted and the level
of TNF-a and b−actin mRNA expression were assessed by semiquan-
titative PCR. Results of representative RT-PCR: similar results were
obtained in 3 (CML and AGE-b2m) or 7 (AGE-HSA) independent
experiments. Abbreviations are: AGE-HSA, HUVEC incubated in the
presence of AGE-HSA followed by ILF; CML, HUVEC incubated
in the presence of CML followed by ILF; AGE-b2m, HUVEC incu-
bated in the presence of AGE-b2m followed by ILF; HSA, HUVEC
incubated in the presence of HSA followed by ILF; b2m, HUVEC in-
cubated in the presence of b2m followed by ILF; 0, HUVEC cultured in
medium followed by ILF; 0-ILF, HUVEC cultured in medium without
no stimulation.
Table 1. Effect of AGEs on TNF-a mRNA expression by stimulated
HUVEC: Densitometric analysis
mRNA expression of TNF-a
(fold of HSA or b2m)Concentration
lg/mL AGE-HSA CML AGE-b2m
50 4.2 ± 2 5.4 ± 1.4b 3.5 ± 0.5b
100 14.8 ± 7.3a 9.3 ± 2.9a 5.7 ± 1.2
200 24 ± 6.9a 11.2 ± 3.6a 10.2 ± 4.4a
Abbreviations are: AGE-HSA, HUVEC incubated in the presence of
AGE-HSA followed by ILF (IL1-a, LPS, IFN); CML, HUVEC incubated in
the presence of CML followed by ILF; AGE-b2m, HUVEC incubated in the
presence of AGE-b2m followed by ILF. TNF-a mRNA levels normalized to the
levels of b−actin mRNA expression and relative mRNA content are expressed
as fold of HSA or b2m values. Data are expressed as mean ± SE of 3 (CML and
AGE-b2m) or 7 (AGE-HSA) independent experiments.
aP < 0.05 vs. HSA or b2m; bP < 0.05 vs. 200 lg/mL CML or AGE-b2m.
(AGE-HSA, CML, and AGE-b2m). AGE-albumin has
been prepared as being the most frequent AGEs used
in in vitro studies. CML, prevalent AGEs, are elevated
in sera of diabetic and uremic patients, and accumu-
late in atherosclerotic lesions and in glomerular tissue of
diabetic patients and rodents [16]. CML, one of the best-
characterized AGE products, binds to RAGE and acti-
vates intracellular transcription factors [17]. AGE-b2m,
detected in urine and sera of uremic patients, plays a
200 100 50 200 0 0-ILF
A
eNOS
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Fig. 3. Effect of advanced glycation end-products (AGEs) on eNOS
gene expression by stimulated human umbilical vein cords endothelial
cells (HUVEC). HUVEC were incubated for 24 hours with increasing
concentrations of AGE-HSA (A), CML (B), AGE-b2m (C), HSA, or
b2m (0 to 200 lg/mL). The cells were then stimulated by ILF for 6
hours. Total RNA was extracted and the level of eNOS and b−actin
mRNA expression was assessed by semiquantitative PCR. Results of
representative RT-PCR: similar results were obtained in 3 independent
experiments. Abbreviations are in the legend of Figure 2.
Table 2. Effect of AGEs on eNOS mRNA expression by stimulated
endothelial cells: Densitometric analysis
mRNA expression of eNOS
(% of HSA or b2m)Concentration
lg/mL AGE-HSA CML AGE-b2m
50 55.7 ± 16.2a 54.3 ± 3.5a 45 ± 20a
100 42.9 ± 14.2a,b 45.9 ± 4.3a 38 ± 10a
200 28.7 ± 10.3a,b 49.9 ± 2.8a 28.4 ± 10a
eNOS mRNA levels normalized to the levels of b−actin mRNA expression
and relative mRNA content was expressed as percent of HSA or b2m values.
Data are expressed as mean ± SE of 3 independent experiments. See Table 1 for
abbreviations.
aP < 0.05 vs. HSA or b2m; bP < 0.05 vs. 50 lg/mL AGEs.
role in the development of dialysis-related amyloidosis
(DRA) [12] and stimulates the production of TNF-a,
IL1-b [21], and IL-6 [22] by mononuclear leukocytes. The
three different types of in vitro-prepared AGEs increased
TNF-a mRNA expression and production and decreased
eNOS mRNA and protein expression by HUVEC in a
dose-dependent fashion and in the same range of con-
centration (50 to 200 lg/mL). It is noteworthy that the
concentrations of AGEs that were used in this in vitro
setup were of the same order of magnitude as those
found, in vivo, in patients with diabetes and in those
with end-stage renal disease [8]. As shown by Miyata et
al [21], purified AGE proteins formed in vivo have the
same biological effects as AGE proteins prepared in vitro.
Accordingly, one may reasonably expect that the findings
in the present study using AGEs prepared in vitro may
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Fig. 4. Effect of AGE-HSA and CML on eNOS gene expression by
nonstimulated human umbilical vein cords endothelial cells (HUVEC).
HUVEC were incubated for 48 hours with increasing concentrations of
AGE-HSA (A), CML (B), or HSA (0–200 lg/mL). Total RNA was
extracted and the level of eNOS and b—actin mRNA expression was
assessed by semiquantitative PCR. Results of representative RT-PCR:
similar results were obtained in 3 independent experiments. Abbrevi-
ations are: AGE-HSA, HUVEC incubated in the presence of AGE-
HSA; CML, HUVEC incubated in the presence of CML; HSA, HU-
VEC incubated in the presence of HSA; 0, HUVEC cultured in medium
without no stimulation.
be considered relevant to evaluate the endothelial be-
havior in presence of elevated AGE compounds. High
glucose levels or glucose derivatives, such as reactive car-
bonyls, which may contribute to an abnormal endothelial
cell activity [10], could not have any confounding action
in our experiments after having dialyzed the AGEs’
solutions.
In the first step we examined the effect of ILF (IL1-a,
LPS, IFN) on TNF-a production and mRNA expression.
TNF-a secretion and TNF-a mRNA expression were un-
detectable in nonstimulated HUVEC. Exposure to ILF
for 24 hours stimulated the production of TNF-a. The
expression of TNF-a mRNA was detected after six hours
of incubation with ILF. These results confirm previous
studies which showed that human endothelial cells ex-
press TNF-a mRNA and produce TNF-a after expo-
sure to agents such as LPS, IL1-a, IL1-b , TNF-a and/or
IFN-c [23, 24]. The association ILF was most efficient
in stimulating was HUVEC. Preliminary experiments
demonstrated that IL1-a and LPS had a weak stimulatory
effect, confirming the report of Ranta et al [24]. There-
fore, we used ILF stimulation to evaluate a possible
additive action of AGEs incubated at concentrations
comparable to that previously reported [23, 24]. The en-
dotoxin levels in all AGEs samples were found to be less
than 0.2 ng/mL (<0.96 EU/mL), which are at least 500-
fold under the concentration essential for TNF-a HU-
VEC stimulation (1 to 10 lg/mL LPS) [23, 24]. These
findings confirm that the changes are due to AGEs effect
without the endotoxin contamination.
In uremia, diabetes, aging, as well as in atherosclero-
sis, chronic vascular inflammation is always present [25,
26], with cytokine overproduction and AGEs formation.
Therefore, the in vitro model we used may be considered
to mimic such situation of inflammation, in presence of
elevated AGEs compounds.
In our experiments AGEs have stimulated the produc-
tion of TNF-a by ILF treated HUVEC and the TNF-a
mRNA expression was enhanced. As mentioned above,
TNF-a secretion and TNF-a mRNA expression were un-
detectable in nonstimulated HUVEC, and AGEs alone
did not affect TNF-a production and TNF-a mRNA ex-
pression. Previous studies have shown that AGEs pro-
mote TNF-a secretion by macrophages [27, 28], but there
are no data concerning the effect of AGEs on endothe-
lial cells. Amore et al [29] found that Amadori prod-
ucts increase mRNA expression and synthesis of TNF-a
by endothelial cells. TNF-a, a proinflammatory cytokine
secreted mainly by activated macrophages and T lympho-
cytes, is clearly involved in the pathogenesis of inflamma-
tion [14] and seems to play a role in the development
of diabetic nephropathy and atherosclerosis [30]. TNF-a
may also cause a reduction of the constitutively expressed
NOS mRNA in HUVEC by shortening the half-life of
eNOS mRNA. This effect, which is time and dose depen-
dent, is observed with very low concentrations of TNF-a
(0.1 ng/mL) [31]. In our study eNOS mRNA expression
was depressed in presence of AGE-HSA, CML, or AGE-
b2m. To the best of our knowledge, these data are the first
to report that AGEs prepared with human proteins af-
fect stimulated or nonstimulated HUVEC eNOS mRNA
expression.
The relative low concentrations of TNF-a found in the
supernatant of cultured HUVEC could be an explana-
tion for the diminished eNOS expression, and it is tempt-
ing to speculate that the autocrine action of endothelial
TNF-a, as already found for its own control [23], could
affect, locally, eNOS expression [31]. In our study the
production of TNF-a by ILF-stimulated HUVEC was
detected after 24 hours of incubation at a level of 0.1
to 0.3 ng/106 cells. The reduced eNOS mRNA expres-
sion occurred after six hours, far before TNF-a could
be detected. Moreover, the AGEs-related decrease in
eNOS mRNA expression was also observed in nonstim-
ulated endothelial cells, which did not express TNF-a
mRNA expression or production. Such data could not
support a possible role of an autocrine TNF-a process
and point at another mechanism to explain the AGEs-
related decrease in eNOS mRNA and protein expression.
The decrease in eNOS mRNA and protein expression
could not be affected by endotoxines in AGEs samples
(their levels less than 0.2 ng/mL) because it is below
the concentration that causes a decrease in eNOS pro-
tein and mRNA levels (2.5 lg/mL LPS) [32]. An effi-
cient inhibition of AGEs-RAGE interaction, assessed
in using monoclonal anti-RAGE antibodies, was found
to abrogate the reduction of eNOS mRNA expression
and to blunt the increase of TNF-a mRNA expression
induced by AGEs, demonstrating that the AGEs actions
on eNOS and TNF-a expression were directly mediated
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Fig. 5. Inhibition of AGE-HSA interaction
with RAGE using monoclonal anti-RAGE
antibodies: eNOS mRNA expression. HU-
VEC were preincubated for 3 hours with
anti-RAGE antibody or IgG2a isotype con-
trol prior to AGEs stimulation. HUVEC were
then incubated for 24 hours with AGE-HSA
or HSA and then stimulated by ILF for 6 hours
(A). After preincubation with anti-RAGE an-
tibodies, HUVEC were incubated for 48 hours
with AGE-HSA or HSA (B). Total RNA was
extracted and the level of eNOS and b−actin
mRNA expression was assessed by semiquan-
titative PCR. Results of representative RT-
PCR: similar results were obtained in 3 in-
dependent experiments. Abbreviations are in
the legend of Figure 2 (for A) and Figure 4
(for B). +, addition of indicated AGE-HSA,
HSA, anti-RAGE antibody, and/or negative
control (IgG); —, absence of the above.
ILF-stimulated HUVEC
β-actin
TNF-α
AGE-HSA (200 µg/mL)
AGE-HSA (100 µg/mL)
HSA (200 µg/mL)
HSA (100 µg/mL)
Anti-RAGE Ab
Negative control (IgG)
+ − − + − − + − −
− + − − + − − − −
− − + − − + − + −
− − − − − − − − −
+ + + − − − − − −
− − − + + + − − −
Fig. 6. Inhibition of AGE-HSA interaction
with RAGE using monoclonal anti-RAGE
antibodies: TNF-a mRNA expression. HU-
VEC were preincubated for 3 hours with
anti-RAGE antibody or IgG2a isotype con-
trol prior to AGEs stimulation. HUVEC were
then incubated for 24 hours with AGE-HSA
or HSA and then stimulated by ILF for 6
hours. Total RNA was extracted and the level
of TNF-a and b−actin mRNA expression was
assessed by semiquantitative PCR. Results of
representative RT-PCR: similar results were
obtained in 2 independent experiments. Ab-
breviations are in the legend of Figure 2. +,
addition; −, absence.
AGE-HSA HSA O
Fig. 7. Effect of AGE-HSA on eNOS protein levels by nonstimulated
endothelial cells. Western blot analysis of HUVEC exposed to 200
lg/mL AGE-HSA or HSA for 72 hours. Similar results were obtained
in 4 independent experiments.
by RAGE. Such results are in accordance with the results
of recent studies, which have shown that interruption of
AGEs-receptor interaction, in diabetic rodents, might re-
verse the inadequate vascular permeability, and suppress
accelerated atherosclerotic process [33, 34].
This combined effect of AGEs, elevation of TNF-a,
and decrease of eNOS may have an additive impact on
endothelial cells function to eventually explain vascular
inflammation and impaired vasodilation [35, 36] observed
in situations characterized by high AGEs formation.
In accord with these findings are the reports showing
that the eNOS activity and eNOS protein and mRNA
of bovine endothelial cells are depressed when exposed
to AGE-BSA [37, 38]. AGEs-related decrease of eNOS
mRNA expression associated with low NOS activity and
NO avaibility, by quenching NO [39], reduces endothe-
lial cells’ antiplatelet activity and increases expression of
adhesion molecules [40], as well as PMN-endothelial cell
adhesion [41]. This fits well with the recent data, which
have shown that AGEs enhance the expression of en-
dothelial cell adhesion molecules [10, 11]. Moreover, as
NO is a vascular immunomodulator, lower NO produc-
tion may affect inflammation processes and be involved
in the pathogenesis of atherosclerosis [7, 40, 41]. Because
atherosclerosis is associated with a depressed eNOS pro-
tein expression, such situation leads to a vicious circle
[42]. In addition, NO may prevent vascular lesions in
inhibiting vascular smooth muscle cell (VSMC) pro-
liferation and migration [36, 43]. In consequence, by
modifying NO bioavailability, AGEs may affect VSMC
relaxation, proliferation, and migration, and therefore,
accelerate vascular remodeling.
CONCLUSION
We have shown that different in vitro prepared human
AGEs stimulate the mRNA expression and secretion of
TNF-a and reduce the eNOS mRNA and protein expres-
sion in human endothelial cells. The additive effects of
elevated TNF-a and depressed NO activity on endothe-
lial functions and intercellular interaction may really be
involved in the development of impaired vascular func-
tion and remodeling seen in uremia, diabetes mellitus,
and aging.
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